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geneAbstract The pathogenesis of essential hypertension (EH) is affected by genetic and environmental
factors. Mutations in hypertension-related genes can affect blood pressure (BP) via alteration of salt
and water reabsorption by the nephron. The genes of the renin-angiotensin system (RAS) have been
extensively studied because of the well documented role of this system in the control of BP. It has
been previously shown that Angiotensin II type 1 receptor (ATR1) gene polymorphism could be
associated with increased risk of EH. So, in the current study, we evaluated the frequency of
ATR1 (A1166C) polymorphism in relation to EH in a group of Egyptian population. The study
population included 83 hypertensive patients and 60 age and sex matched healthy control subjects.
Restriction fragment length polymorphism – Polymerase chain reaction (RFLP – PCR) was used
for the analysis of A1166C polymorphism of ATR1 genes in peripheral blood samples of all patients
and controls. The results revealed that there was a positive risk of developing EH when having the T
allele whether in homozygous or heterozygous state. From this work, it was concluded that there
was an association between ATR1 (A1166C) gene polymorphism and the risk of developing EH.
 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Essential hypertension is a major risk factor for several cardio-
vascular diseases. It is a complex trait resulting from the inter-
actions of multiple genetic and environmental factors.Moreover, not only genetic but also epigenetic inheritance
plays a significant role. One can speculate that hypertension
develops as a consequence of ‘‘errors” in the well-
coordinated regulatory systems of blood pressure.1 This com-
mon disease-common variant concept suggests that the genetic
heterogeneity underlying hypertension susceptibility could be
relatively small. Therefore, it makes sense that variation in
genes related to hypertension should be studied.2 In recent
years, the research is directed toward analyses of the disease
on genetic level and explanation of the genetic bases of this
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techniques has resulted in widespread endeavors to dissect
the genetic factors and their molecular defects accounting for
hypertension in various populations. Today, the state-of-the-
art approach toward the diagnosis of primary hypertension
involves analysis of the genetic bases for the disorder.3
The renin-angiotensin system (RAS) is a group of related
hormones that act together to regulate BP by maintaining vas-
cular tone and the balance of water and sodium. Angiotensin
II type 1 receptor (ATR1) is among the components that are
involved in the activation/effector cascade of the RAS. Ang
II is a potent vasoconstrictor that exerts most of its known cel-
lular actions through the Ang II type 1 receptor (AT1). The
Ang II AT1 receptor is a membrane bound G protein-
coupled receptor that mediates the vasoconstrictive effects of
Ang II.4,5 Although many polymorphisms of the ATR1 gene
(accession number: P30556) have been identified, the
(A1166C) polymorphism has been the most extensively stud-
ied. The (A1166C) polymorphism is in a non-coding region
of the gene, and therefore the amino acid sequence of the
receptor is not altered. In theory, associations with ACE geno-
type may be due to functional variants in nearby loci, and/or
related genetic polymorphism.6
The ATR1 gene (A1166C) polymorphism has been shown
to be associated with oxidative stress in heart failure patients.7
It has been also shown to interrupt the ability of microRNA-
155 to attenuate translation, resulting in augmented ATR1
expression.8 This suggests a potential functional mechanism
by which the 3’UTR A1166C polymorphism can lead to
increased oxidative stress and the development of cardiovascu-
lar diseases. Taken together, these findings are interpreted to
support the hypothesis that ATR1 (A1166C) polymorphism
is related to augmented angiotensin II activity and important
clinical end points, including EH and cardiovascular disease.9
Genetic polymorphisms in components of the RAS including
ATR1 (A1166C) are suggested to be associated with the
pathogenesis of EH. However, the obtained results are still
debated.4
The analysis of RAS related genetic polymorphism of
patients having EH has been carried out in Egyptian popula-
tion on a limited scale. So, this study aimed to determine the
association of genetic polymorphisms of the Angiotensin II
type 1 receptor (A1166C) gene polymorphism with EH in a
cohort of genetically homogenous EH patients and normoten-
sive controls (case–control study).
2. Materials and methods
The current study included 83 EH patients (55 males and 28
females) with mean age of 53.5 ± 7.4 years old. Also 60
healthy subjects (32 males and 28 females) matching in age
and sex (51.3 ± 8.8 years old) were included as control group.
The patients were selected from the outpatient clinic of the
Cardiology Department, General Alexandria University
Hospital, during the period between 2009 and 2010. A written
consent was obtained from all subjects accepting to participate
in the study for both the clinical part and the genetic study. All
subjects under study were subjected to thorough history taking
and clinical examination with special emphasis on BP and
BMI. Peripheral blood samples were collected from all subjects
and routine investigations were done including FBS, lipidprofile (total cholesterol, LDL – ch, HDL – ch and triglyc-
erides) and renal function tests (serum urea and creatinine).
Essential hypertension was diagnosed in individuals with a
systolic blood pressure (SBP) > 140 mmHg and/or a diastolic
blood pressure (DBP) > 90 mmHg or in those currently
receiving anti-hypertensive therapy. Secondary forms of hyper-
tension were excluded based on clinical history and laboratory
investigations. The normotensive controls were healthy indi-
viduals with a negative history of hypertension and with a
SBP < 140 mmHg and DBP < 90 mmHg measured on three
separate occasions, and also all study subjects were non-
diabetic with normal renal functions.
2.1. Genotyping
DNA samples were isolated from peripheral blood lympho-
cytes by the standard phenol extraction method. The ATR1
(A1166C) polymorphism was detected by RFLP PCR using
the following primers: 50- GCA GCA CTT CAC TAC CAA
ATG GGC - 30 as forward primer and 50 CAG GAC AAA
AGC AGG CTA GGG AGA - 30 as reverse primer. The
RFLP PCR reaction for amplification of ATR1 gene was car-
ried out as follows: 15 ll PCR master mix, 3 ll DNA template
(0.5 lg), forward and reverse primers 1 ll each (30 pmole) and
completed to a final volume of 30 ll with 10 ll nuclease free
water. PCR condition consisted of an initial denaturation at
95 C for 5 min, followed by 35 cycles of denaturation at
94 C for 1 min, annealing at 55 C for 1 min, and elongation
at 72 C for 1 min, with a final extension at 72 C for 7 min.
Amplification resulted in a 255-bp product. Then the PCR
product was digested with the restriction enzyme Bacillus spe-
cies (BsuRI) (FastDigest HaeIII (BsuRI), Fermentas Chemi-
cal Co., Germany, Cat#FD0154). Electrophoresis on a 3% (w/
v) agarose gel containing 0.5 lg/ml ethidium bromide (Sigma–
Aldrich, St. Louis, USA) and UV transillumination were used
for analysis.
Statistical Analysis was carried out using SPSS version 15.0
software and the following tests were used for data analysis:
Chi squared (v2) test, Monte Carlo Probability (MCP) and
Fisher’s Exact Probability (FEP) were used for analysis of cat-
egorical data, T-test was used for comparison between means,
and Odds ratio (OR) was used for the measurement of
association.
3. Results
The results showed that there was a highly statistically signif-
icant difference (p< 0.001, and p< 0.001) in both the systolic
BP (145.28 ± 7.0 mmHg) and the mean diastolic BP (91.2
± 2.15 mmHg) of hypertensive patients when compared to
their corresponding values (117.33 ± 4.27 mmHg and 79.17
± 3.46 mmHg), respectively of normotensive subjects (control
group).
Genotyping of ATR1(A1166C) polymorphism, detected
after PCR amplification and BsuRI digestion, yielded two
bands of 231 and 24 bp in the presence of the restriction site
(C allele) and only one band of 255 bp in the absence of the
restriction site (A allele). Heterozygotes (AC) produce two
bands of 255 and 231 bp10 (Figs. 1 and 2).
The results revealed that the frequency of the AC genotype
was significantly (v2 = 10.612*, p= 0.005) increased in
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Figure 1 Agarose gel (3%) electrophoresis for RFLP digested PCR products. Lane 1: 100 bp base pair marker. Lane 2: undigested PCR
product of a patient with AA genotype (255 bp) (positive control). Lane (3, 5, 7): unrestricted fragments of PCR products of patients with
AA genotype (255 bp). Lane 6: restricted PCR product of a patient with AC genotype (255, 231 bp). Lane 4: restricted PCR product of a
patient with CC genotype (231 bp).
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Figure 2 Polyacrylamide gel electrophoresis of ATR1 (A1166C) polymorphism bands after digestion by Bsu RI, lane 1: bp marker
(100 bp). Lanes 2, 3, 5 and 6: AA homozygote. Lane 7: CC homozygote and lane (4, 8): AC heterozygote.
Table 1 The frequency of ATR1 (A1166C) polymorphic
genotypes in normotensive subjects (control) and hypertensive
patients.
Control (n = 60) Patients (n = 83) v2 (p)
No. % No. %
ATR1 genotypes
AA 53 88.3 55 66.3 9.175* (0.002)
AC 7 11.7 21 25.3 4.111* (0.043)
CC 0 0.0 7 8.4 FEp = 0.022*
v2 (p) 10.612 (0.005*)
v2: Chi square test.
FEp: p value for Fisher Exact test.
* Statistically significant at p 6 0.05.
Table 2 The frequency of ATR1 A and C alleles in
normotensive subjects (control) and hypertensive patients.
Control (n = 60) Patients (n = 83) v2 (p)
Freq. % Freq. %
ATR1 alleles
A 113 94.16 131 78.92 12.930* (<0.001)
C 7 5.83 35 21.08
v2: Chi square test.
FEp: p value for Fisher Exact test.
* Statistically significant at p 6 0.05.
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developing EH when having the CC and AC genotypes and the
results were highly statistically significant (OR = 2.89,
p= 0.022) (Tables 1 and 3).
The frequency of C allele was significantly (v2 = 12.930*,
p< 0.001) increased in hypertensive patients. Furthermore,there was a positive risk of developing EH when having the
C allele whether in homozygous or heterozygous state and
the results were highly statistically significant (OR = 4.313,
p< 0.001) (Tables 2 and 4).
4. Discussion
Cardiovascular diseases are rapidly emerging as a major health
concern in most developing countries, including Egypt, and
Table 3 The risk of having ATR1 (A1166C) polymorphism
in relation to essential hypertension.
Control
(n = 60)
Patients
(n = 83)
OR 95% CI
(LL – UL)
v2 (p)
No. % No. %
ATR1 genotypes
AA 53 88.3 55 66.3 – – –
AC 7 11.7 21 25.3 2.891* 1.14–7.36 5.227*
(0.022)
CC 0 0.0 7 8.4 – – FEp =
0.015*
FEp: p value for Fisher Exact test.
v2: Chi square test.
* Statistically significant at p 6 0.05.
Table 4 The risk of having C allele in relation to essential
hypertension.
Control
(n = 60)
Patients
(n = 83)
OR 95% CI
(LL – UL)
v2 (p)
Freq. % Freq. %
ATR1 alleles
A 113 94.16 131 78.92 – – 12.930*
(<0.001)C 7 5.83 35 21.08 4.313* 1.84–10.09
v2: Chi square test
* Statistically significant at p 6 0.05.
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ity and mortality from cardiovascular disease. Very recently,
Arafa and Ez-elarab11 calculated the prevalence of prehyper-
tension and hypertension based on the data of 6671 individuals
from the EDHS 2008. The prevalence of prehypertension and
hypertension in Egypt were 57.2% and 17.6%, respectively.
Only 25.2% of the population had normal BP levels of
<120/80 mmHg.
The analysis of ATR1 (A1166C) gene polymorphism of
patients having EH has been carried out in Egyptian popula-
tion on a limited scale. The potential role of the ATR1 gene
in predisposition to hypertension is controversial. Since Bon-
nardeaux et al.,12 previously reported higher prevalence of
the C1166 allele among hypertensive than among normoten-
sive subjects, a large number of studies have explored the rela-
tionship between ATR1 gene polymorphism and HT. In the
current study, the percentage of the AC and CC genotypes
was significantly more frequent in hypertensive patients than
in the control group (p< 0.001). Moreover, the C allele was
the risk allele for hypertension where the study subjects carry-
ing C allele were at more than sevenfold higher risk for hyper-
tension (OR= 4.313, p< 0.001).
The results of this study were in accordance with studies
that were conducted in Budapest, Hungary,13 in French
women,14 in Serbia,15 in Japanese subjects,16, Han Chinese17
and in Tunisian population.18 On the contrary, there was no
significant association between the A1166C polymorphism
and hypertension in a German population,19,20 on non-
Caucasian populations21 and in Hispanic population22.5. Conclusion and recommendations
The present study provided an additional observation concern-
ing ATR1 (A1166C) polymorphic genotypes in a sample of
Egyptian patients with EH. From this study it was concluded
that:
1. The frequency of C allele was higher in hypertensive
patients (22%) as compared to control subjects (6%). On
the contrary, the A allele was less frequent in hypertensive
patients (79%) as compared to control subjects (94%).
2. Homozygousity for the ATR1 C allele was a risk factor for
EH. Moreover, the presence of ATR1 C allele, whether in
homozygous or heterozygous state, was a risk factor for
EH.
It is recommended that:
1. Future studies should investigate the influence of genetic
polymorphisms of the ATR1 (A1166C) polymorphic geno-
types on response to anti-hypertensive therapy.
2. Future studies should evaluate the association of the ATR1
(A1166C) polymorphic genotypes in other human diseases
affected by alterations in the RAS.
Conflict of interest
The authors declare that there are no conflict of interests.
References
1. Kunes J, Zicha J. The interaction of genetic and environmental
factors in the etiology of hypertension. Physiol Res 2009;58:
S33–41.
2. Balam-ortiz E, Esquivel-villarreal A, Alfaro-ruiz L, Carrillo K,
Elizalde A, Gil T, et al. Variants and haplotypes in angiotensino-
gen gene are associated with plasmatic angiotensinogen level in
Mexican population. Am J Med Sci 2011;342:205–11.
3. Elzanaty F, Way A. Egypt Demographic and Health Survey 2008.
Recommended citation. Ministry of Health El-Zanaty and Asso-
ciates and Macro International. Chapter 17. Adult Health Issues
2009;11:228–35.
4. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hyper-
tension: novel means for renin – angiotensin – aldosterone system
modulation and emerging device-based approaches. Eur Heart J
2011;32:2739–47.
5. Santos RA, Ferreira AJ, Simo˜es E, Silva AC. Recent advances in
the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis.
Exp Physiol 2008;93:519–27.
6. Puthucheary Z, Skipworth JR, Rawal J, Loosemore M, Van
Someren K, Montgomery HE. The ACE gene and human
performance: 12 years on. Sports Med 2011;41:433–48.
7. Cameron VA, Mocatta TJ, Pilbrow AP, Frampton CM,
Troughton RW, Richards AM, et al. Angiotensin type-1 receptor
A1166C gene polymorphism correlates with oxidative stress levels
in human heart failure. Hypertension 2006;47:1155–61.
8. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ,
Chotani M, et al. The human angiotensin II type 1 receptor +1166
A/C polymorphism attenuates microrna-155 binding. J Biol Chem
2007;282:24262–9.
9. Poirier O, Georges JL, Ricard S, Arveiler D, Ruidavets JB, Luc G,
et al. New polymorphisms of the angiotensin II type 1 receptor
Angiotensin II type 1 receptor (A1166C) gene polymorphism 169gene and their associations with myocardial infarction and blood
pressure: the ECTIM study. Etude Cas-Te´moin de l’Infarctus du
Myocarde. J Hypertens 1998;16:1443–7.
10. Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D,
Ksiazek A. Genetic polymorphisms of the renin-angiotensin
system in end-stage renal disease. Nephrol Dial Transplant
2006;21:979–90.
11. Arafa NA, Ez-elarab HS. Epidemiology of prehypertension and
hypertension among Egyptian adults. Egypt J Commun Med
2011;29:1–18.
12. Bonnardeaux A, Davies E, Jeunmaitre X. Angiotensin II type 1
receptor gene polymorphisms in human essential hypertension.
Hypertension 1994;24:63–9.
13. Szombathy T, Szalai C, Katalin B, Palicz T, Romics L, Csa´sza´r A.
Association of angiotensin II type 1 receptor polymorphism with
resistant essential hypertension. Clin Chim Acta 1998;269:91–100.
14. Tiret L, Blanc H, Ruidavets JB. Gene polymorphisms of the
rennin-angiotensin system in relation to hypertension and parental
history of myocardial infarction and stroke: the PEGASE study. J
Hypertens 1998;16:37–44.
15. Stankovic´ A, Zivkovic M, Glisic´ S, Alavantic´ D. Angiotensin II
type 1 receptor gene polymorphism and essential hypertension in
Serbian population. Clin Chim Acta 2003;327:181–5.
16. Kobashi G, Hata A, Ohta K, Yamada H, Kato EH, Minakami H,
et al. A1166C variant of angiotensin II type 1 receptor gene isassociated with severe hypertension in pregnancy independently of
T235 variant of angiotensinogen gene. J Human Genet
2004;49:182–6.
17. Niu W, Qi Y, Hou S, Zhai X, Zhou W, Qiu C. Haplotype-based
association of the renin-angiotensin-aldosterone system genes
polymorphisms with essential hypertension among Han Chinese:
the Fangshan study. J Hypertens 2009;27:1384–91.
18. Mehri S, Mahjoub S, Hammami S, Zaroui A, Frih A, Betbout F.
Renin-angiotensin system polymorphisms in relation to hyperten-
sion status and obesity in a Tunisian population. Mol Biol Rep
2011;23:309–16.
19. Schmidt S, Beige J, Walla-Friedel M. A polymorphism in the gene
for the angiotensin II type 1 receptor is not associated with
hypertension. J Hypertens 1997;15:1385–8.
20. Morisawa T, Kishimoto Y, Kitano M, Kawasaki H, Hasegawa J.
Influence of angiotensin II type 1 receptor polymorphism on
hypertension in patients with hypercholesterolemia. Clin Chim
Acta 2001;304:91–7.
21. Takami S, Katsuya T, Rakugi H. Angiotensin II type 1 receptor
gene polymorphism is associated with increase of left ventricular
mass but not with hypertension. Am J Hypertens 1998;11:316–21.
22. Bautista LE, Vargas CI, Oro´stegui M, Gamarra G. Population-
based case-control study of renin-angiotensin system genes poly-
morphisms and hypertension among Hispanics. Hypertens Res
2008;31:401–8.
